Aulos Bioscience is an immuno-oncology company that aims to revolutionize cancer patient care through its computationally designed IL-2 therapeutics. The company's flagship clinical candidate, AU-007, has been engineered to leverage a patient's own IL-2 to induce tumor killing while minimizing associated toxicities. Founded in 2020 by Biolojic Design and ATP, Aulos Bioscience secured a substantial $40M Series A investment from Apple Tree Partners. The startup, based in the United States, combines world-class machine learning with a deep understanding of the immune system and is poised to make significant contributions to biotechnology and healthcare. Aulos Bio's focus on leveraging the power of the immune system to combat cancer positions it as a promising player in the evolving immuno-oncology landscape. With its groundbreaking approach and strong financial backing, Aulos Bioscience presents an exciting opportunity for potential investors and stakeholders in the cancer care industry.
General Information
BounceWatch is an independent company data service, not affiliated with Aulos Bioscience. To contact Aulos Bioscience, visit aulosbio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Aulos Bioscience compare?
A PDF of Aulos Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Aulos Bioscience soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Aulos Bioscience on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Aulos Bioscience
Business keywords: immuno-oncology, IL-2 therapeutics, cancer care, immune system, clinical candidate, tumor killing, immunosuppression, toxicity, solid tumors, antibody development, cancer immunotherapies, Biolojic Design, ATP funding
Funding Rounds & Investors (2)
View AllAulos Bioscience Alternatives & Competitors
View All AlternativesMerus was acquired by Genmab. To see what’s new, visit Genmab.
#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021
Improving patient outcomes through innovations in biological therapeutics
FAQ About Aulos Bioscience
Source: BounceWatch company record for Aulos Bioscience, https://www.bouncewatch.com/company/aulos-bioscience, updated 1 July 2026. When citing, please name BounceWatch and link this page.